Hong Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hong Jia has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Zetian Li
Southwest Medical University
6 shared publicationsXue Zhang
Southwest Medical University
5 shared publicationsYating Peng
Southwest Medical University
5 shared publicationsLiangchuan Zhang
School of Public Health, Southwest Medical University, Luzhou City, China
4 shared publicationsWangdong Xu
School of Public Health, Southwest Medical University, Luzhou, China
4 shared publicationsYuan Kong
Southwest Medical University
4 shared publications
Latest Publications
- 1 January 2025
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 50, 1-11
Relationship of irisin and apelin levels with sarcopenia and body composition in community-dwelling older adults: a paired case–control study
Irisin and apelin levels continue to decrease with age, and although many previous studies have explored their association with sarcopenia and body composition, there is still a paucity of evidence relating to them in community-dwelling elderly populations. The aim of this study was to provide new evidence for the association of irisin and apelin with sarcopenia in older adults. This case–control study included 80 individuals with sarcopenia and 80 individuals without sarcopenia. The definition of sarcopenia was based on the Asian Working Group for Sarcopenia 2019 criteria. Plasma levels of irisin and apelin were measured using an enzyme-linked immunosorbent assay. Conditional logistic regression analysis was performed to estimate odds ratios (ORs) and 95% CIs. The sarcopenia group exhibited significantly lower levels of irisin (73.75 ± 30.97 ng/mL vs. 131.15 ± 88.38 ng/mL, p < 0.001) and apelin (21.51 ± 14.89 ng/mL vs. 27.87 ± 14.41 ng/mL, p = 0.007) compared to the control group. Increased levels of irisin (OR, 0.98, 95% CI, 0.97–0.99) and apelin (OR, 0.97, 95% CI, 0.95–0.99) were associated with a decreased risk of sarcopenia. In women, irisin was positively associated with body mass index, intracellular water (ICW), extracellular water (ECW), total water (TW), protein, mineral, fat, fat-free mass, skeletal muscle mass (SMM), percentage body fat, waist circumference, visceral fat area, and basal metabolic rate. Apelin was positively associated with ICW, ECW, TW, protein, and SMM (all p < 0.05). In men, positive correlations were found between irisin, apelin, and handgrip strength (all p < 0.05). Receiver operating characteristic analysis showed that irisin and apelin had moderate predictive power in identifying sarcopenia. Plasma irisin and apelin were lower than in controls in elderly patients with sarcopenia, and elevated levels of irisin and apelin were associated with a reduced risk of sarcopenia. In addition, irisin and apelin levels are associated with body composition and irisin showed a stronger ability to predict sarcopenia in women.
- 1 January 2025
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 50, 1-11
Relationship of irisin and apelin levels with sarcopenia and body composition in community-dwelling older adults: a paired case–control study
Irisin and apelin levels continue to decrease with age, and although many previous studies have explored their association with sarcopenia and body composition, there is still a paucity of evidence relating to them in community-dwelling elderly populations. The aim of this study was to provide new evidence for the association of irisin and apelin with sarcopenia in older adults. This case–control study included 80 individuals with sarcopenia and 80 individuals without sarcopenia. The definition of sarcopenia was based on the Asian Working Group for Sarcopenia 2019 criteria. Plasma levels of irisin and apelin were measured using an enzyme-linked immunosorbent assay. Conditional logistic regression analysis was performed to estimate odds ratios (ORs) and 95% CIs. The sarcopenia group exhibited significantly lower levels of irisin (73.75 ± 30.97 ng/mL vs. 131.15 ± 88.38 ng/mL, p < 0.001) and apelin (21.51 ± 14.89 ng/mL vs. 27.87 ± 14.41 ng/mL, p = 0.007) compared to the control group. Increased levels of irisin (OR, 0.98, 95% CI, 0.97–0.99) and apelin (OR, 0.97, 95% CI, 0.95–0.99) were associated with a decreased risk of sarcopenia. In women, irisin was positively associated with body mass index, intracellular water (ICW), extracellular water (ECW), total water (TW), protein, mineral, fat, fat-free mass, skeletal muscle mass (SMM), percentage body fat, waist circumference, visceral fat area, and basal metabolic rate. Apelin was positively associated with ICW, ECW, TW, protein, and SMM (all p < 0.05). In men, positive correlations were found between irisin, apelin, and handgrip strength (all p < 0.05). Receiver operating characteristic analysis showed that irisin and apelin had moderate predictive power in identifying sarcopenia. Plasma irisin and apelin were lower than in controls in elderly patients with sarcopenia, and elevated levels of irisin and apelin were associated with a reduced risk of sarcopenia. In addition, irisin and apelin levels are associated with body composition and irisin showed a stronger ability to predict sarcopenia in women.
- 19 November 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (1) , 5-13
Circulating irisin levels in patients with sarcopenia: a systematic review and meta-analysis
Key summary points AbstractSection Aim Determine whether irisin levels are reduced in sarcopenia patients compared to non sarcopenia populations. AbstractSection Findings Irisin levels were significantly lower in patients with sarcopenia (SMD: −1.28; 95% CI −1.65, −0.90; I2 = 92% p < 0.01). The level of irisin is positively correlated with SMI (r: 0.62; 95% CI 0.31, 0.81 P < 0.01) and grip (r: 0.47; 95% CI 0.23, 0.66; P < 0.01). AbstractSection Message Reduced irisin levels in the old people population are strongly associated with sarcopenia.
- 19 November 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (1) , 5-13
Circulating irisin levels in patients with sarcopenia: a systematic review and meta-analysis
Key summary points AbstractSection Aim Determine whether irisin levels are reduced in sarcopenia patients compared to non sarcopenia populations. AbstractSection Findings Irisin levels were significantly lower in patients with sarcopenia (SMD: −1.28; 95% CI −1.65, −0.90; I2 = 92% p < 0.01). The level of irisin is positively correlated with SMI (r: 0.62; 95% CI 0.31, 0.81 P < 0.01) and grip (r: 0.47; 95% CI 0.23, 0.66; P < 0.01). AbstractSection Message Reduced irisin levels in the old people population are strongly associated with sarcopenia.
- Open Access
- 8 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
The unique presentation of the relationship between red blood cell folate and appendicular skeletal muscle mass: a cross-sectional study
The overconsumption of folic acid has been associated with deleterious health effects; however, the extant body of research on this matter remains controversial. The principal objective of our investigation was to scrutinize the correlation between red blood cell (RBC) folate levels and appendicular skeletal muscle mass (ASM) among adult individuals. A total of 4117 adults aged over 20 years were included. The weighted prevalence of low muscle mass status (LMMS) was 14.50%. The correlation between RBC folate and ASM showed an inverted U-shaped curve. When the RBC folate concentration is below 500 nmol/L, ASM increases with increasing RBC folate concentration. However, when the RBC folate level exceeds 500 nmol/L, ASM decreases with increased RBC folate level. After correcting multiple confounding factors, a positive correlation was found between RBC folate and LMMS (p < 0.001). Compared with the RBC folate first quartile, the multivariable-adjusted ORs and 95% CIs of the second quartile, third quartile, and highest quartile were 1.08(0.81–1.44), 1.06(0.79–1.43), and 1.96(1.47–2.61), respectively. Our research suggested that excessive levels of RBC folate may be associated with an increased risk of LMMS in adults. Thus, being more cautious when considering folic acid supplementation is recommended.
- 8 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessThe unique presentation of the relationship between red blood cell folate and appendicular skeletal muscle mass: a cross-sectional study
The overconsumption of folic acid has been associated with deleterious health effects; however, the extant body of research on this matter remains controversial. The principal objective of our investigation was to scrutinize the correlation between red blood cell (RBC) folate levels and appendicular skeletal muscle mass (ASM) among adult individuals. A total of 4117 adults aged over 20 years were included. The weighted prevalence of low muscle mass status (LMMS) was 14.50%. The correlation between RBC folate and ASM showed an inverted U-shaped curve. When the RBC folate concentration is below 500 nmol/L, ASM increases with increasing RBC folate concentration. However, when the RBC folate level exceeds 500 nmol/L, ASM decreases with increased RBC folate level. After correcting multiple confounding factors, a positive correlation was found between RBC folate and LMMS (p < 0.001). Compared with the RBC folate first quartile, the multivariable-adjusted ORs and 95% CIs of the second quartile, third quartile, and highest quartile were 1.08(0.81–1.44), 1.06(0.79–1.43), and 1.96(1.47–2.61), respectively. Our research suggested that excessive levels of RBC folate may be associated with an increased risk of LMMS in adults. Thus, being more cautious when considering folic acid supplementation is recommended.
- 7 March 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 15 (3) , 1-8
Comparison of six screening methods for sarcopenia among rural community-dwelling older adults: a diagnostic accuracy study
Key summary points AbstractSection Aim To determine the diagnostic efficacy of six screening tools for sarcopenia. AbstractSection Findings 44.5% were diagnosed as sarcopenia in men and 39.1% in women. SarSA-Mod had a high screening value after redefining the cutoff value, and the Ishii test may be our better screening tool for assessing sarcopenia. The SARC-F’s modified versions showed significantly increased sensitivity. AbstractSection Message The Ishii test is the best tool among the six screening tools for assessing sarcopenia in the study.
- 7 March 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 15 (3) , 1-8
Comparison of six screening methods for sarcopenia among rural community-dwelling older adults: a diagnostic accuracy study
Key summary points AbstractSection Aim To determine the diagnostic efficacy of six screening tools for sarcopenia. AbstractSection Findings 44.5% were diagnosed as sarcopenia in men and 39.1% in women. SarSA-Mod had a high screening value after redefining the cutoff value, and the Ishii test may be our better screening tool for assessing sarcopenia. The SARC-F’s modified versions showed significantly increased sensitivity. AbstractSection Message The Ishii test is the best tool among the six screening tools for assessing sarcopenia in the study.
- Open Access
- 3 May 2023
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 27 (5) , 329-339
Effects of Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Older Adults with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Study
- 3 May 2023
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 27 (5) , 329-339
Open AccessEffects of Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Older Adults with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Study
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 17
Novel inflammatory biomarkers in the prognosis of COVID-19
Background: The central role of inflammatory progression in the development of Coronavirus disease 2019 (COVID-19), especially in severe cases, is indisputable. However, the role of some novel inflammatory biomarkers in the prognosis of COVID-19 remains controversial. Objective: To assess the effect of some novel inflammatory biomarkers in the occurrence and prognosis of COVID-19. Methods: We systematically retrieved the studies related to COVID-19 and the inflammatory biomarkers of interest. The data of each biomarker in different groups were extracted, then were categorized and pooled. The standardized mean difference was chosen as an effect size measure to compare the difference between groups. Results: A total of 90 studies with 12,059 participants were included in this study. We found higher levels of endocan, PTX3, suPAR, sRAGE, galectin-3, and monocyte distribution width (MDW) in the COVID-19 positive groups compared to the COVID-19 negative groups. No significant differences for suPAR and galectin-3 were detected between the severe group and mild/moderate group of COVID-19. In addition, the deaths usually had higher levels of PTX3, sCD14-ST, suPAR, and MDW at admission compared to the survivors. Furthermore, patients with higher levels of endocan, galectin-3, sCD14-ST, suPAR, and MDW usually developed poorer comprehensive clinical prognoses. Conclusions: In summary, this meta-analysis provides the most up-to-date and comprehensive evidence for the role of the mentioned novel inflammatory biomarkers in the prognosis of COVID-19, especially in evaluating death and other poor prognoses, with most biomarkers showing a better discriminatory ability.
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 17
Open AccessNovel inflammatory biomarkers in the prognosis of COVID-19
Background: The central role of inflammatory progression in the development of Coronavirus disease 2019 (COVID-19), especially in severe cases, is indisputable. However, the role of some novel inflammatory biomarkers in the prognosis of COVID-19 remains controversial. Objective: To assess the effect of some novel inflammatory biomarkers in the occurrence and prognosis of COVID-19. Methods: We systematically retrieved the studies related to COVID-19 and the inflammatory biomarkers of interest. The data of each biomarker in different groups were extracted, then were categorized and pooled. The standardized mean difference was chosen as an effect size measure to compare the difference between groups. Results: A total of 90 studies with 12,059 participants were included in this study. We found higher levels of endocan, PTX3, suPAR, sRAGE, galectin-3, and monocyte distribution width (MDW) in the COVID-19 positive groups compared to the COVID-19 negative groups. No significant differences for suPAR and galectin-3 were detected between the severe group and mild/moderate group of COVID-19. In addition, the deaths usually had higher levels of PTX3, sCD14-ST, suPAR, and MDW at admission compared to the survivors. Furthermore, patients with higher levels of endocan, galectin-3, sCD14-ST, suPAR, and MDW usually developed poorer comprehensive clinical prognoses. Conclusions: In summary, this meta-analysis provides the most up-to-date and comprehensive evidence for the role of the mentioned novel inflammatory biomarkers in the prognosis of COVID-19, especially in evaluating death and other poor prognoses, with most biomarkers showing a better discriminatory ability.
- Open Access
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1029941
Association between weight change and risk of metabolic abnormalities in non-overweight/obese and overweight/obese population: A retrospective cohort study among Chinese adults
Objectives: To explore the effects of weight change on the risk of metabolic abnormalities in the Chinese population.Methods: A total of 1895 metabolically healthy adults aged 21–78 years completed anthropometric and biological measurements at baseline (2012) and at an eight year follow-up (2020). Based on absolute weight change and relative weight change, the participants were split into five classes. A Cox proportional hazards regression model was used to estimate the relative risk (RR) and 95% confidence intervals (95% CI) for the risk of metabolic abnormalities using stable weight as the reference group. Stratified analysis was used to explore this relationship in participants with different baseline body mass index (BMI) levels.Results: During the follow-up period, 35.41% of the participants retained a stable weight, and 10.71% had metabolic abnormalities. After covariate adjustment, for every kilogram gained over eight years, the risk of developing metabolic abnormalities increased by 22% (RR: 1.094; 95% CI: 1.063–1.127). Compared with stable weight participants, weight gain of 2–4 Kg and weight gain ≥ 4 Kg exhibited significantly higher risks of metabolic abnormalities, with RR of 1.700 (95% CI 1.150–2.513) and 1.981 (95% CI 1.372–2.859), respectively. A weight gain of ≥ 4 Kg had an opposite effect on the overweight/obesity and non-overweight/obesity groups, with an increased risk of metabolic abnormalities only in the non-overweight/obesity group (RR, 2.291; 95% CI, 1.331–3.942). Moreover, weight loss ≥ 4 Kg significantly reduced the risk of metabolic abnormalities only among overweight/obese adults (RR 0.373; 95% CI 0.154–0.906). Similar results were observed in relative body weight change analyses.Conclusions: Long-term excessive body weight gain is positively associated with an increased risk of metabolic abnormalities among adults with non-overweight/obesity, whereas long-term body weight loss is a protective factor for metabolic health among adults with overweight/obesity.
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1029941
Open AccessAssociation between weight change and risk of metabolic abnormalities in non-overweight/obese and overweight/obese population: A retrospective cohort study among Chinese adults
Objectives: To explore the effects of weight change on the risk of metabolic abnormalities in the Chinese population.Methods: A total of 1895 metabolically healthy adults aged 21–78 years completed anthropometric and biological measurements at baseline (2012) and at an eight year follow-up (2020). Based on absolute weight change and relative weight change, the participants were split into five classes. A Cox proportional hazards regression model was used to estimate the relative risk (RR) and 95% confidence intervals (95% CI) for the risk of metabolic abnormalities using stable weight as the reference group. Stratified analysis was used to explore this relationship in participants with different baseline body mass index (BMI) levels.Results: During the follow-up period, 35.41% of the participants retained a stable weight, and 10.71% had metabolic abnormalities. After covariate adjustment, for every kilogram gained over eight years, the risk of developing metabolic abnormalities increased by 22% (RR: 1.094; 95% CI: 1.063–1.127). Compared with stable weight participants, weight gain of 2–4 Kg and weight gain ≥ 4 Kg exhibited significantly higher risks of metabolic abnormalities, with RR of 1.700 (95% CI 1.150–2.513) and 1.981 (95% CI 1.372–2.859), respectively. A weight gain of ≥ 4 Kg had an opposite effect on the overweight/obesity and non-overweight/obesity groups, with an increased risk of metabolic abnormalities only in the non-overweight/obesity group (RR, 2.291; 95% CI, 1.331–3.942). Moreover, weight loss ≥ 4 Kg significantly reduced the risk of metabolic abnormalities only among overweight/obese adults (RR 0.373; 95% CI 0.154–0.906). Similar results were observed in relative body weight change analyses.Conclusions: Long-term excessive body weight gain is positively associated with an increased risk of metabolic abnormalities among adults with non-overweight/obesity, whereas long-term body weight loss is a protective factor for metabolic health among adults with overweight/obesity.
- 29 October 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (7) , 776-786
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis
Background: No study has yet systematically evaluated the effect of antidiabetic therapy on clinical outcomes of COVID-19 patients with type 2 diabetes (T2D). Objective: We aimed to evaluate the effect of different antidiabetic therapy on clinical outcomes of COVID-19 patients with T2D. Methods: We comprehensively retrieved the published research which examined the effect of antidiabetic therapy on clinical outcomes of COVID-19 patients with T2D. The odds ratio (OR) and its 95% confidence interval (95% CI) for clinical outcomes were calculated using the random-effects model, and meta-regression was adopted to evaluate the potential sources of heterogeneity between studies. Results: A total of 54 studies were included in this study. We found that the use of metformin (OR = 0.66, 95% CI: 0.58-0.75), SGLT-2i (OR = 0.80, 95% CI: 0.73-0.88), and GLP-1ra (OR = 0.83, 95% CI: 0.70-0.98) were significantly associated with lower mortality risk in COVID-19 patients with T2D, while insulin use might unexpectedly increase the ICU admission rate (OR = 2.32, 95% CI: 1.34-4.01) and risk of death (OR = 1.52, 95% CI: 1.32-1.75). No statistically significant associations were identified for DPP-4i, SUs, AGIs, and TZDs. Conclusion and Relevance: We demonstrated that the usage of metformin, SGLT-2i, and GLP-1ra could significantly decrease mortality in COVID-19 patients with T2D. The heterogeneity across the studies, baseline characteristics of the included patients, shortage of dosage and the duration of antidiabetic drugs and autonomy of drug selection might limit the objectivity and accuracy of results. Further adequately powered and high-quality randomized controlled trials are warranted for conclusive findings.
- 29 October 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (7) , 776-786
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis
Background: No study has yet systematically evaluated the effect of antidiabetic therapy on clinical outcomes of COVID-19 patients with type 2 diabetes (T2D). Objective: We aimed to evaluate the effect of different antidiabetic therapy on clinical outcomes of COVID-19 patients with T2D. Methods: We comprehensively retrieved the published research which examined the effect of antidiabetic therapy on clinical outcomes of COVID-19 patients with T2D. The odds ratio (OR) and its 95% confidence interval (95% CI) for clinical outcomes were calculated using the random-effects model, and meta-regression was adopted to evaluate the potential sources of heterogeneity between studies. Results: A total of 54 studies were included in this study. We found that the use of metformin (OR = 0.66, 95% CI: 0.58-0.75), SGLT-2i (OR = 0.80, 95% CI: 0.73-0.88), and GLP-1ra (OR = 0.83, 95% CI: 0.70-0.98) were significantly associated with lower mortality risk in COVID-19 patients with T2D, while insulin use might unexpectedly increase the ICU admission rate (OR = 2.32, 95% CI: 1.34-4.01) and risk of death (OR = 1.52, 95% CI: 1.32-1.75). No statistically significant associations were identified for DPP-4i, SUs, AGIs, and TZDs. Conclusion and Relevance: We demonstrated that the usage of metformin, SGLT-2i, and GLP-1ra could significantly decrease mortality in COVID-19 patients with T2D. The heterogeneity across the studies, baseline characteristics of the included patients, shortage of dosage and the duration of antidiabetic drugs and autonomy of drug selection might limit the objectivity and accuracy of results. Further adequately powered and high-quality randomized controlled trials are warranted for conclusive findings.